02/04/2018
RetinaLyze System automatically screen for Diabetic Retinopathy and
Age-related Macular Degeneration within 30 sec.
Every person with diabetes is at risk of going blind. At any time around a third of people with diabetes have some form of eye health complication, with devastating and wide-ranging social and economic impacts on people living with diabetes, their families and communities.
Almost all vision impairment and blindness from diabetic eye disease can be prevented through effective diabetes management, early detection of eye problems through regular eye exams, and timely treatment*
With strategic investment and leadership, we can reduce the burden of diabetic eye disease.
In some countries, where governments have made the commitment to prioritise access to good quality diabetic eye care for all citizens, diabetic eye disease is no longer the leading cause of blindness among working age people.
Addressing this growing threat on a global scale requires similar commitment from all stakeholders to ensure that accessible, affordable, appropriate and safe eye care services become an integral part of diabetes management, care and support for all people with diabetes.
The RetinaLyze software represents the best of two worlds. Automated screenings for Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD) and a national and international Telemedicine Solution.
Today one of the most common diseases is Diabetes. The pandemic figures of the world show that the number of diabetes patients will double to 1,8 billion people in 2025. To prevent vision loss from Diabetic Retinopathy (small bleedings in the retina inside
the eye), every diabetic person must be examined by an ophthalmologist at least once a year.
The development in the no. of ophthalmologists compared to no. of diabetic and pre-diabetic patients in the next 10 years show a large gap. Even today the ophthalmologists have large problems in handling the screenings because they have far too many patients. We know that only 30-40 % of all screened diabetics actually need to be examined by an ophthalmologist, because they have yet to develop DR. In that way, the RetinaLyze system is perfect to divide individuals in “good and bad” and is used to refer only the patients in need for a manual check-up by the ophthalmologist.
The RetinaLyze system is a vector-based algorithm and the patented invention relates to a method for assessing the presence or absence of retinal lesion(s) in an image.
The RetinaLyze screening is an analysis performed on a fundus photo. The fundus photo is taken with a non-mydriatic fundus camera, connected to a digital system, which can store the digital images and upload them to the web application.
The RetinaLyze software provides a precise result within 30 seconds and the system has the fastest and most accurate algorithm (sensitivity 96,6%) to detect Diabetic Retinopathy and AMD on the market.
RetinaLyze detects : Small Haemorrhages - Micro Aneurisms in the DR mode.
RetinaLyze detects: Hard exudates as Drusen in the AMD mode. RetinaLyze only reacts if one or more of these lesions are present at the Retina.
The use of RetinaLyze is to decide if there are early signs of Diabetic Retinopathy or not. The Screening is a YES/NO screening to be used for patients with no prior diagnosed DR.
RetinaLyze is expanding rapidly and next step is Japan, Australia and India. Today RetinaLyze is present in 35 countries and cooperates with hospitals, Optical Chains, Diabetic Clinics and Ophthalmologists.
Despite international recommendations, many diabetes patients do not have their eyes screened every year due to long waiting lists at
the ophthalmologist or the cost of the screening. Furthermore, almost 300 million diabetics do not know they have diabetes and hence are not screened for Diabetic Retinopathy.
How do we do it?
Using RetinaLyze software and low cost high quality fundus camera RetinaLyze Kenya Ltd. can screen your patients over the course of only a couple of weeks.
The software is online and delivers easy understandable results which are available within 30 seconds, with one camera we are able to mass screen up to 150 patients per day.
RetinaLyze Kenya Ltd is cooperating with Local ophthalmologists online and can refer the clients if necessary for further checkup and treatment.
We can provide you with the staff and facilities needed.
The Ophthalmologist will be able to access the pictures on our screening website and be able to analyse them at their own desk before they meet the patients. Reducing the cost of time and optimize treatment.
This is a short introduction to our system, but if you need further information, please do not hesitate to contact Retinalyze kenya ltd on +254 717491833.
You can book on our calendar www.retinalyzekenya.com for trial screening and visit as at
ROOM 16,2ND FLOOR, QAMAR PLAZA BEHIND NOMANENO.
Try Retinalyze for free: If you wish to try RetinaLyze, you can do so for free. You'll be provided with a RetinaLyze license for a month, installation of the software (optional) and instructions in use of the software as well as communicating with
